Navigation Links
Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations
Date:7/21/2008

PITTSBURGH, July 21 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today the appointment of Daniel E. Crookshank as vice president - Investor Relations and as a member of the company's senior leadership team. Reporting to Chief Financial Officer Edward J. Borkowski, Crookshank is responsible for all investment community communication as well as for the development and direction of activities that proactively promote Mylan to the investment community.

"Dan has a well-deserved reputation as an outstanding, senior investor relations professional," said Mylan Vice Chairman and CEO Robert J. Coury. "His extensive international experience - together with his comprehensive knowledge of finance and solid accounting background - will serve the company well going forward. We're excited to have an individual with Dan's talents joining our Mylan team."

Crookshank served most recently as vice president - Investor Relations for Rockwell Collins, a global manufacturer of communications and aviation electronics solutions for commercial and military customers worldwide. During his 18-year career with Rockwell Collins and Rockwell International, he served in a number of increasingly responsible positions within Finance. Crookshank also completed accounting assignments with National Steel Corporation and H.J. Heinz Corporation. He began his business career with the public accounting firm Deloitte, Haskins & Sells, now Deloitte & Touche.

Crookshank earned a bachelor's degree in business administration from Robert Morris University and an MBA from the Katz Graduate School of Business at the University of Pittsburgh.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
2. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
3. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
4. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
5. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
6. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
7. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
8. Vincent Corso and Daniel Trush Win 2007 Avis We Try Harder Awards
9. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
10. Global Health Trax Joins Fight Against Autism With Jenny McCarthy and Generation Rescue
11. Bernadette Peters Joins Board of Directors of Standing Tall, Innovative Program for Multiply Disabled Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
Breaking Medicine Technology: